COVAX-19
COVAX-19 (or SpikoGen) is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine, in collaboration with CinnaGen, a private company with operations in the Middle East. It is under clinical trial in collaboration with the Iranian company CinnaGen.[2][3][4]
Vaccine description
Spikogen[1]
- Full and emergency authorisations
Medical uses[edit]
It requires two doses 21 days apart given by intramuscular injection.[3]
Pharmacology[edit]
COVAX-19 is a recombinant protein subunit.[5]